Mayer Chen, Abu-Ghanem Yasmin, Dotan Zohar A, Barshack Iris, Fridman Eddie
Institute of Pathology, Sheba Medical Center, Tel Hashomer, Affiliated with Tel Aviv University, Tel Aviv, Israel.
Urology Department, Sheba Medical Center, Tel Hashomer, Affiliated with Tel Aviv University, Tel Aviv, Israel.
Adv Urol. 2022 Aug 29;2022:1589040. doi: 10.1155/2022/1589040. eCollection 2022.
Oncocytoma is one of the most common benign kidney tumors, accounting for 3-7% of all solid renal masses. Diagnosing oncocytomas using renal biopsy remains a controversy in the uro-pathologic community. With the increasing use of biopsies for assessment of renal lesions, reaching this pathologically benign diagnosis may prevent further surgical measures and have significant clinical benefit.
To demonstrate our center's results using renal biopsy to diagnose oncocytomas and to suggest that this diagnosis can be made with high success rates.
, , . From our center's database, we retrospectively identified and retrieved all cases of oncocytoma diagnosed between the years 2011 and 2020 by renal biopsy. Medical records of those patients were then reviewed to view follow-up meetings and imaging of the lesions biopsied. . In 21 biopsies performed on 19 patients, diagnosis was supported by subsequent follow-up averaging at 3.44 years per patient. . The lesions exhibited benign behavior during follow-up after biopsy, consistent with the diagnosis of oncocytoma.
Our study demonstrates that with good patient selection and proficient cooperation between urologists, radiologists and dedicated uro-pathologists, correctly diagnosing oncocytomas using RCB is a viable task. . Oncocytomas are benign lesions of the kidney. In our study, we reviewed all cases of oncocytomas pathologically diagnosed using renal biopsy from our center's database. We found that in subsequent follow-up later to biopsy, the lesions displayed benign behavior consistent with oncocytoma. The use of percutaneous biopsies to reach this diagnosis could save patients more extensive surgeries.
嗜酸细胞瘤是最常见的良性肾肿瘤之一,占所有实性肾肿块的3%-7%。在泌尿病理学界,使用肾活检诊断嗜酸细胞瘤仍存在争议。随着活检在评估肾病变中的应用越来越多,获得这种病理良性诊断可能避免进一步的手术措施,并具有显著的临床益处。
展示我们中心使用肾活检诊断嗜酸细胞瘤的结果,并表明这种诊断可以获得很高的成功率。
……从我们中心的数据库中,我们回顾性地识别并检索了2011年至2020年间通过肾活检诊断的所有嗜酸细胞瘤病例。然后查阅这些患者的病历,以查看随访情况和活检病变的影像学检查。……在对19名患者进行的21次活检中,后续平均每位患者3.44年的随访支持了诊断。……活检后的随访期间,病变表现出良性行为,与嗜酸细胞瘤的诊断一致。
我们的研究表明,通过良好的患者选择以及泌尿外科医生、放射科医生和专业泌尿病理学家之间的熟练合作,使用肾芯活检正确诊断嗜酸细胞瘤是一项可行的任务。……嗜酸细胞瘤是肾脏的良性病变。在我们的研究中,我们回顾了我们中心数据库中所有经肾活检病理诊断的嗜酸细胞瘤病例。我们发现,在活检后的后续随访中,病变表现出与嗜酸细胞瘤一致的良性行为。使用经皮活检做出这种诊断可以为患者节省更广泛的手术。